FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma By Ogkologos - January 28, 2026 257 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TRANSCEND FL-MZL Cohort Source RELATED ARTICLESMORE FROM AUTHOR ESMO Advocates for Equal Access to Optimal Cancer Care for all Patients with Cancer at the 79th World Health Assembly Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer MOST POPULAR Speaking a thousand words – how a cancer image collection is... September 8, 2021 Dalpiciclib plus Fulvestrant in Pretreated HR-positive, HER2-negative Advanced Breast Cancer November 24, 2021 What People in Asian American and Pacific Islander Communities Should Know... September 5, 2023 EMA Recommends Extension of Therapeutic Indications for Acalabrutinib June 18, 2025 Load more HOT NEWS Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced... Preparación para el fin de la emergencia de salud pública (PHE)... New Device Could “Hear” Stiffening of Extracellular Matrix to Determine Where... Epcoritamab Shows a Manageable Safety and Robust Antitumour Activity in Heavily...
